Cancer Treatment Reviews
Volume 30, Issue 7 , Pages 661-664, November 2004

Adjuvant chemotherapy with uracil–tegafur prolongs overall survival in people with primary adenocarcinoma of the lung:☆☆☆☆☆☆

Abstracted from: Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil–tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713–21.

Cancer Care Ontario, c/o 620 University Avenue, Toronto, Ontario M5G 2L7, Canada

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: This study was supported by Taiho Pharmaceutical Company, Tokyo, Japan.

☆☆ For Correspondence: Yukito Ichinose, Department of Thoracic Oncology, National Kyushu Cancer Center, Notame, Minami-ku, Fukuoka, Japan. E-mail: yichinos@nk-cc.go.jp.

☆☆☆ Abstract provided by Bazian Ltd, London.

PII: S0305-7372(04)00145-8

doi:10.1016/j.ctrv.2004.08.003

Cancer Treatment Reviews
Volume 30, Issue 7 , Pages 661-664, November 2004

Article Tools